Advate

Phase 3Small molecule

Takeda

Advate is one of 38 small molecule programs targeting Von Willebrand disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseRecruiting

HemophiliaActive, not recruiting

Hemophilia aCompleted

Von Willebrand DiseasePhase 3

Recruiting

HemophiliaPreclinical

Active, not recruiting

Hemophilia aPhase 3

Completed

Competition

Competitive Landscape

33 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Approved

17 2

Rayos

RRoxane Laboratories

Approved

1 3

Cyklokapron

Efanesoctocog Alfa

6 5

Marstacimab

Pfizer

Phase 3

1 6

Advate

Takeda

Phase 3

4 7

PF-06741086

Pfizer

Phase 3

2 8

Rfviia

Roche

Phase 3

2 9

NXT007

Roche

Phase 3

2 10

SR604

EEquilibra Bioscience LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Von Willebrand Disease

NCT07129343

Q2 2028

Post-ApprovalRecruiting

Hemophilia a

NCT06864975

Q2 2030

Phase 3Recruiting

Von Willebrand Disease (VWD)

NCT05582993

Clinical

Trials by Indication[1]

Hemophilia A4 trials

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Completed·OOregon Health and Science University·Phase 3·NCT02306694·16 enrolled

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

Recruiting·RRunhui WU·Phase 4·NCT06864975·110 enrolled

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

Completed·BBaxalta now part of Shire··NCT02078427·951 enrolled

Show 1 more trial

A Study of ADVATE in People With Hemophilia A in India

Completed·BBaxalta now part of Shire·Phase 4·NCT04985682·50 enrolled

Severe Hemophilia a4 trials

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT02282410·15 enrolled

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Completed·BBioverativ, a Sanofi company·Phase 1/2·NCT03205163·16 enrolled

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Completed·BBioverativ Therapeutics Inc.·Phase 3·NCT01181128·165 enrolled

Show 1 more trial

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Completed· Bayer logo

Bayer·Phase 1·NCT02483208·18 enrolled

Coagulation3 trials

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Unknown status·KKaifeng Pharmaceutical (Group) Co., Ltd.··NCT03747653·12 enrolled

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Completed·JJiangsu Gensciences lnc.·Phase 1·NCT05251090·13 enrolled

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Completed·JJiangsu Gensciences lnc.·Phase 1·NCT04864743·13 enrolled

Haemophilia A2 trials

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens

Unknown status·SSt. James's Hospital, Ireland·Phase 4·NCT02314325·20 enrolled

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00837356·23 enrolled

Von Willebrand disease1 trial

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

Recruiting· Takeda logo

Takeda·Phase 3·NCT07129343·20 enrolled

2 more indications

Hemophilia1 trial

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Completed·BBaxalta now part of Shire··NCT02190149·64 enrolled

Von Willebrand Disease (VWD)1 trial

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease

Recruiting· Takeda logo

Takeda·Phase 3·NCT05582993·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Advate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Advate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Advate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Advate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q2 2030

Trials by Indication[1]

Hemophilia A4 trials

Severe Hemophilia a4 trials

Coagulation3 trials

Haemophilia A2 trials

Von Willebrand disease1 trial

Hemophilia1 trial

Von Willebrand Disease (VWD)1 trial

References

Drug Info

Quick Facts

Related News